{
  "pdfPath": "/home/arkantu/Documentos/Zotero Biblioteca/Neurología/Clinical practice/EFNS Guidelines/Cruccu et al. - 2008 - AAN-EFNS guidelines on trigeminal neuralgia manage.pdf",
  "fileName": "Cruccu et al. - 2008 - AAN-EFNS guidelines on trigeminal neuralgia manage.pdf",
  "relativePath": "Neurología/Clinical practice/EFNS Guidelines/Cruccu et al. - 2008 - AAN-EFNS guidelines on trigeminal neuralgia manage.pdf",
  "text": "European Journal of Neurology 2008, 15: 1013–1028                                                       doi:10.1111/j.1468-1331.2008.02185.x\n\nEFNS GUIDELINES/CME ARTICLE\n\n\nAAN-EFNS guidelines on trigeminal neuralgia management\nG. Cruccua, G. Gronsethb, J. Alksnec, C. Argoffd, M. Brainine, K. Burchielf, T. Nurmikkog and\nJ. M. Zakrzewskah\na\n    Department of Neurological Sciences, La Sapienza University, Rome, Italy; bDepartment of Neurology, University of Kansas, Kansas City,\nUSA; cDivision of Neurosurgery, School of Medicine, University of California, San Diego, USA; dNew York University School of Medicine\nand Cohn Pain Management Center, North Shore University Hospital, Manhasset, USA; eClinical Neurosciences, Department of Clinical\nMedicine and Prevention, Donau-Universität Krems, Krems, Austria; fDepartment of Neurological Surgery, Oregon Health & Science\nUniversity, Portland, USA; gPain Research Institute, Division of Neurological Science, School of Clinical Sciences, University of Liverpool,\nLiverpool, UK; hUniversity College London Hospitals Eastman Dental Hospital, London, UK\n\n\nKey words:                           Several issues regarding diagnosis, pharmacological treatment, and surgical treatment\ntrigeminal neuralgia,                of trigeminal neuralgia (TN) are still unsettled. The American Academy of Neurology\ndiagnosis, neurovascular             and the European Federation of Neurological Societies launched a joint Task Force to\ncontact, MRI, trigeminal             prepare general guidelines for the management of this condition. After systematic\nreﬂex, treatment, anti-              review of the literature the Task Force came to a series of evidence-based recom-\nepileptic drugs, Gasserian           mendations. In patients with TN MRI may be considered to identify patients with\nganglion surgery, micro-             structural causes. The presence of trigeminal sensory deﬁcits, bilateral involvement,\nvascular decompression,              and abnormal trigeminal reﬂexes should be considered useful to disclose symptomatic\ngamma knife                          TN, whereas younger age of onset, involvement of the ﬁrst division, unresponsiveness\n                                     to treatment and abnormal trigeminal evoked potentials are not useful in distin-\nReceived 27 March 2008               guishing symptomatic from classic TN. Carbamazepine (stronger evidence) or ox-\nAccepted 28 March 2008               carbazepine (better tolerability) should be oﬀered as ﬁrst-line treatment for pain\n                                     control. For patients with TN refractory to medical therapy early surgical therapy\n                                     may be considered. Gasserian ganglion percutaneous techniques, gamma knife and\n                                     microvascular decompression may be considered. Microvascular decompression may\n                                     be considered over other surgical techniques to provide the longest duration of pain\n                                     freedom. The role of surgery versus pharmacotherapy in the management of TN in\n                                     patients with multiple sclerosis remains uncertain.\n\n\n                                                                         latest classiﬁcation of the International Headache\nIntroduction\n                                                                         Society,[29] a distinction is made between classical and\nThe American Academy of Neurology (AAN) and the                          symptomatic TN: classical TN (CTN) includes all cases\nEuropean Federation of Neurological Societies (EFNS)                     without an established etiology, i.e. idiopathic, as well\ndecided to develop scientiﬁcally sound, clinically rele-                 as those with potential vascular compression of the ﬁfth\nvant guidelines to aid specialists and non-specialists in                cranial nerve, whereas the diagnosis of symptomatic\nthe management of trigeminal neuralgia (TN), by                          TN (STN) is made in cases secondary to tumour, MS,\naddressing its diagnosis, pharmacological treatment,                     structural abnormalities of the skull base, and the like.\nand surgical treatment.                                                  It should be noted that categorization of TN into typ-\n   The International Association for the Study of Pain                   ical and atypical forms is based on symptom constel-\n(IASP) deﬁnes TN as sudden, usually unilateral, severe,                  lation, and not etiology, and will not be discussed\nbrief, stabbing, recurrent episodes of pain in the dis-                  further in this review.\ntribution of one or more branches of the trigeminal                         The ﬁrst issue facing the clinician caring for a patient\nnerve.[54] The annual incidence of TN is 4 to 5/                         with TN is accurately distinguishing symptomatic from\n100,000.[34] TN is the most common neuralgia. In the                     classical TN. The diagnostic portion of this parameter\n                                                                         addresses the following questions:\n                                                                         1. How often does routine neuroimaging (CT, MRI)\nCorrespondence: Prof. Giorgio Cruccu, Dip. Scienze Neurologiche,\n                                                                             identify a cause (excluding vascular contact) of TN?\nViale Università 30, 00185 Roma, Italy (tel.: +39 06 49694209; fax:\n+39 06 49914758; e-mail: cruccu@uniroma1.it).                            2. Which clinical or laboratory features accurately\n                                                                             identify patients with STN?\nThis is a Continuing Medical Education article and can be found with\ncorresponding questions on the internet at http://www.efns.org/\n                                                                         3. For patients with classical TN does high resolution\ncontent.php?pid=132. Certiﬁcates for correctly answering the                 MRI accurately identify patients with neurovascular\nquestions will be issued by the EFNS.                                        compression?\n\n\nÓ 2008 The Author(s)\nJournal compilation Ó 2008 EFNS                                                                                                       1013\n\f1014        G. Crucca et al.\n\n\n\nThe ﬁrst line therapy of trigeminal neuralgia is phar-                          expertise. Conﬂicts of interest were disclosed. Panelists\nmacological, if for no other reason than in most cases it                       were not compensated.\nis immediately available and usually eﬀective. Intro-                              We searched MEDLINE, EMBASE and the Cochrane\nduction of phenytoin in the 1940s and carbamazepine in                          library. Searches extended from the time of database\nthe 1960s changed the management of TN consider-                                inception to 2006. All searches used the following syn-\nably, which previously had been almost exclusively                              onyms for TN: trigeminal neuralgia, tic douloureux,\nsurgical. The pharmacological portion of this parame-                           facial pain or trigeminal neuropathy. Search terms were\nter addresses the following questions:                                          used as text words or MESH headings as appropriate.\n4. Which drugs have shown eﬃcacy in the treatment of                            The primary search was supplemented by a secondary\n    CTN?                                                                        search using the bibliography of retrieved articles and\n5. Which drugs have shown eﬃcacy in the treatment of                            knowledge from the expert panel. Only full original\n    STN?                                                                        communications were accepted. Panel members reviewed\n6. Is there evidence of eﬃcacy of intravenous drugs in                          abstracts and titles for relevance. Then, at least two panel\n    acute exacerbations of TN?                                                  members reviewed papers meeting inclusion criteria. An\nWhen medical treatment fails either due to poor pain                            additional panel member arbitrated disagreements.\ncontrol or because of intolerable side eﬀects surgery is                           The methods of classifying evidence adopted by\noften considered the next option. The timing of surgery                         AAN and EFNS are very similar, those of grading the\nand choice of surgery then becomes the next issue to                            recommendations—though largely compatible—diﬀer\nface the patient. Surgical interventions are varied and                         in a few points. A detailed comparison of the two\nare best classiﬁed according to the principal target:                           methods of classiﬁcation and grading can be found in\nperipheral techniques targeting portions of the trigem-                         Appendix 1 (supplementary material). The classiﬁca-\ninal nerve distal to the Gasserian ganglion; percutane-                         tion of the identiﬁed studies was agreed by American\nous Gasserian ganglion techniques targeting the                                 and European authors (details can be found in the\nganglion itself; gamma knife radiosurgery targeting the                         evidence Tables 1–9). This was not possible for the\ntrigeminal root, and posterior fossa vascular decom-                            grading of recommendations. The present article,\npression techniques.                                                            meant for the European Journal of Neurology, used the\n7. When should surgery be oﬀered?                                               EFNS grading of recommendations.[10]\n8. Which surgical technique gives the longest pain free\n    period with fewest complications and good quality\n                                                                                Results\n    of life?\n9. Which surgical techniques should be used in patients\n                                                                                1. Diagnosis\n    with multiple sclerosis?\n                                                                                Question 1\n                                                                                For patients with trigeminal neuralgia without non-\nSearch Methods\n                                                                                trigeminal neurological symptoms or signs, how often\nThe AAN and EFNS identiﬁed an expert panel of TN                                does neuroimaging (CT, MRI) identify a cause\nexperts and general neurologists with methodological                            (excluding vascular contact)?\n\nTable 1 Diagnosis: frequency at which neuroimaging identiﬁed patients with symptomatic TN\n\nFirst Author                                                            Data                                        Total TN       STN\nYear                  Class Sampling                  Population        collection    TN criteria          Modality Patients       Patients (CI)\n\nCruccu 2006 [16]      III      Consecutive pts        Referral centre prospective     IHS                  MRI       120           16 MS\n                                with TN                                                                                            6 tumours\nSato 2004 [69]        III      Consecutive patients   University        retrospective IASP                 MRI or    61            7 tumours\n                                with TN                                                                     CT\nGoh 2001 [27]         III      Consecutive patients   National          retrospective Not stated           MRI       40a           4 masses\n                                with TN and MRI        dental centre\nMajoie 1998 [50]      III      Consecutive patients   University        retrospective Not stated           MRI       22            3 tumours\n                                with TN and MRI                                                                                    1 aneurysm\nNomura 1994 [59] IV            Consecutive patients   University        retrospective Not stated           MRI or    164           22 masses\n                                with TN                                                (non-TN              CT\n                                                                                       neurological signs)\n\nPooled Class III                                                                                                     37/243 Yield 15% (11 to 20)\na\n    Patients with non-trigeminal symptoms or signs eliminated. CI: 95% conﬁdence interval.\n\n\n\n                                                                                                                              Ó 2008 The Author(s)\n                                                                       Journal compilation Ó 2008 EFNS European Journal of Neurology 15, 1013–1028\n\f                                                                                                             Trigeminal neuralgia management              1015\n\n\nTable 2 Diagnostic accuracy of clinical features for distinguishing symptomatic TN from classic TN\n\nFirst Author                                          CTN/                   Age            Sensory          First                                Poor rx\nYear                Class       Design    Spectrum    STN     Number         mean±SD        Deﬁcits          division        Bilateral            response\n\nCruccu 2006         I           CO P      Broad       CTN     96             62±12          0/96             28/136          0/96                 –\n [16]                                                 STN     24 (mixed)     51±10          2/24             9/33            0/24\nDe Simone           III         CC P      Narrow      CTN     13             60±12          4/13             8/25            0/13                 –\n 2005 [19]                                            STN     15 (MS)        43±11          10/15            3/23            0/15\nSato 2004 [69]      II          CO R      Broad       CTN     43                                                                                  3/43\n                                                      STN     7 (tumours)                                                                         2/7\nOgutcen-Toller      II          CO R      Broad       CTN     31                                                             0/31\n 2004 [62]                                            STN     7 (masses)                                                     1/7\nGoh 2001 [27]       II          CO R      Broad       CTN     36             60±13          0/36                             0/36                 10/35\n                                                      STN     6 (masses)     54±11          2/6                              0/6                  3/6\nHooge 1995          IV          CS R      Narrow      CTN     0              –              –                                –                    –\n [31]                                                 STN     35 (MS)        51             3/35                             5/35                 2/20\nNomura 1994         II          CO R      Broad       CTN     142            47±13          1/142            11/58           0/58\n [59]                                                                        (n = 58)\n                                                      STN     22 (masses)    48±16          11/22            6/22            0/22\n\nPooled Classes                                                P assoc        <0.0001        <0.001           NS              <0.001               NS\n I-III                                                        Sen% (CI)      –              37 (27 to 49)    23 (15 to 34)   1.4 (0 to 7)         39 (18 to 65)\n                                                              Spe% (CI)      –              98 (96 to 99)    79 (73 to 84)   100 (98 to 100)      83 (74 to 9)\n                                                              Pos LR         –              18.5             1.1             Large                2.3\n\nCO: cohort survey. CC: case control. CS: Case series. P: Prospective data collection. R: Retrospective or not described data collection. CI: 95%\nconﬁdence intervals. P assoc: probability of statistically signiﬁcant association between the presence of the characteristic and the presence of\nsymptomatic STN. Sen: sensitivity. Spe: speciﬁcity. Sensitivities calculated for presence of characteristic in symptomatic TN. Speciﬁcities calculated\nfor absence of characteristic in classical TN. Pos LR: positive likelihood ratio.\n\nTable 3 Diagnostic accuracy of trigeminal reﬂex testing for distinguishing symptomatic TN from classic TN\n\nFirst Author Year                        Class    Design    Spectrum    Ref. Standard       STN A/T         CTN A/T     P assoc      Spe (CI)         Sen (CI)\n\nKimura 1970 [38]                         III      CC P      narrow      Clinical            1/1             1/14        NS           93%              100%\nOngerboer de Visser 1974 [63]            III      CC R      narrow      Clinical            16/16           0/11        <0.0001      100%             100%\nKimura 1983 [37]                         II       CC P      broad       Clinical            10/17           4/93        <0.0001      96%              59%\nCruccu 1990 [17]                         II       CC P      broad       Clinical imaging    4/4             2/30        <0.0003      93%              100%\nCruccu 2006 [16]                         I        CO P      broad       Clinical MRI        23/24           7/96        <0.0001      93%              96%\n\nPooled Classes I-III                                                                        54/62           14/244      <0.0001      94%              87%\n                                                                                                                                     (91 to 97)       (77 to 93)\n\nTrigeminal reﬂex testing: R1 early blink reﬂex after supraorbital stimulation (for ophthalmic division), SP1 early masseter inhibitory reﬂex after\ninfraorbital stimulation (for maxillary division), and SP1 early masseter inhibitory reﬂex after mental stimulation or mandibular tendon reﬂex (for\nmandibular division). A/T: abnormal/total. CO: cohort survey. CC: case control. P: Prospective data collection. R: Retrospective or not described\ndata collection. CI: 95% conﬁdence intervals. P assoc: probability of statistically signiﬁcant association between the presence of the characteristic\nand the presence of symptomatic STN. Sen: sensitivity. Spe: speciﬁcity. Sensitivities calculated for presence of abnormal trigeminal reﬂexes in\nsymptomatic TN. Speciﬁcities calculated for absence of abnormal trigeminal reﬂexes in classical TN.\n\n\nTable 4 Diagnostic accuracy of evoked potentials for distinguishing symptomatic TN from classic TN\n\nAuthor year               Class   Method             Design    Spectrum     Ref. Standard     STN A/T       CTN A/T      P assoc     Sen (CI)         Spe (CI)\n\nLeandri 1988 [43]         III     electrical-TEPs    CC P      narrow       imaging           18/23         9/38         <0.0001     78%              76%\nCruccu 1990 [17]          III     electrical-TEPs    CC P      broad        imaging           4/4           9/30         <0.05       100%             70%\nCruccu 2001 [18]          II      laser-EPs          CC P      broad        MRI               20/20         24/47        <0.0001     100%             49%\nMursch 2002 [57]          II      electrical-TEPs    CO R      broad        Not stated        6/10          13/37        NS          60%              65%\n\nPooled II-III                                                                                 48/57         55/152       <0.0001     84%              64%\n                                                                                                                                     (73 to 92)       (56 to 71)\n\nTEPs, trigeminal evoked potentials; A/T, abnormal/total; CO, cohort survey; CC, case control; P, prospective data collection; R, retrospective or\nnot described data collection; CI, 95% conﬁdence intervals; P assoc, probability of statistically signiﬁcant association between the presence of the\ncharacteristic and the presence of symptomatic STN; Sen, sensitivity; Spe, speciﬁcity. Sensitivities calculated for presence of abnormal evoked\npotentials in symptomatic TN. Speciﬁcities calculated for absence of abnormal evoked potentials in classical TN.\n\n\n\nÓ 2008 The Author(s)\nJournal compilation Ó 2008 EFNS European Journal of Neurology 15, 1013–1028\n\f1016      G. Crucca et al.\n\n\n\nTable 5 Diagnostic accuracy of MRI for identifying abnormal vascular contact in classic TN\n\n                                                                 Ref.                  Symptomatic Asymptomatic\nAuthor year       Class Method            Design Spectrum Masked Standard              NVC/T       NVC/T        P assoc          Sen (CI) Spe (CI)\n\nKorogi 1995 [40] I        3D-TOF          CO P     broad      yes       Symptomatic 12/16             4/16            <0.012     75%       75%\n                                                                         side\nMasur 1995 [52] I         3D-FLASH        CO P     broad      yes       Symptomatic 12/18             10/18           NS         67%       44%\n                                                                         side\nMajoie 1997 [51] III      3D-FISP     CC P         narrow     yes       clinical    10/13             8/113           <0.0001 77%          93%\n                          MP-RAGE\nYamakami 2000 I           CISS-3D-TOF CO P         broad      yes       Symptomatic 14/14             7/30            <0.0001 100%         77%\n [79]                                                                    side\nBenes 2005 [6] I          3D-Fiesta       CO P     broad      yes       Symptomatic 11/21             10/21           NS         52%       52%\n                          3D-FSPGR                                       side\nAnderson 2006     I       3D-TOF          CO P     broad      yes       Symptomatic 42/48             34/48           NS         88%       29%\n [1]                      3D-Gad                                         side\nErbay 2006 [23]   III     CISS-MPR        CO R     broad      yes       Symptomatic 30/40             10/40           <0.0001 75%          75%\n                                                                         side\n\nPooled            I-III                                                                131/170        83/286          <0.0001 77%          71%\n                                                                                                                              (70–83)      (65–76)\n\nNVC/T: neurovascular contact/total. CO: cohort survey. CC: case control. P: Prospective data collection. R: Retrospective or not described data\ncollection. CI: 95% conﬁdence intervals. P assoc: probability of statistically signiﬁcant association between the presence of the characteristic and\nthe presence of TN. Sen: sensitivity. Spe: speciﬁcity. Sensitivities calculated for presence of neurovascular contact on the symptomatic side.\nSpeciﬁcities calculated for absence of neurovascular contact on the asymptomatic side.\n\n\nEvidence. Five articles (one graded Class IV) reported                       Simone et al. 2005).[19] Four studies were judged to\nthe results of head imaging on consecutive patients                          have a moderately low risk of bias because of a cohort\ndiagnosed with TN (Table 1). Four studies included                           design with a broad spectrum of patients. However,\ncohorts of TN patients assembled at University and                           these studies collected data retrospectively and were\ntertiary centres with a presumed interest in TN. Because                     thus graded Class II.[27,59,62,69] We found one pro-\nmore complicated and potentially less representative TN                      spective Class I study.[16] In these studies involvement\npatients get treated at such centres, these studies were                     of the ﬁrst trigeminal division and unresponsiveness to\njudged to be at risk for referral bias and thus graded                       treatment were not associated with a signiﬁcant increase\nClass III.[16,27,50,69] Yields of brain imaging ranged                       in the risk of STN. Younger age was signiﬁcantly\nfrom 10 to 18%. Combining Class III studies results in                       associated with increased risk of STN. However, in\npooled estimate of yield of 15% (95% CI, 11 to 20).                          these studies there was considerable overlap in the age\n                                                                             ranges of patients with CTN and STN. Thus, although\nConclusions. For patients with trigeminal neuralgia                          younger age increases the risk of ﬁnding STN, the\nwithout non-trigeminal neurological symptoms, routine                        diagnostic accuracy of age as a predictor of STN was\nneuroimaging possibly identiﬁes a cause in up to 15%                         too low to be clinically useful. The presence of trigem-\nof patients. (Four Class III studies.)                                       inal sensory deﬁcits and bilateral involvement was sig-\n                                                                             niﬁcantly more common in patients with STN.\nQuestion 2                                                                   However, many patients with normal sensation and\nFor patients with trigeminal neuralgia, which clinical or                    unilateral involvement of the trigeminal nerve were\nlaboratory features accurately identify patients with                        found to have a cause of their TN (Figure 1).\nSTN?                                                                            Nine studies looked at the diagnostic accuracy of\n                                                                             electrophysiological testing in distinguishing STN from\nEvidence. We found seven papers (one graded Class IV)                        CTN patients. Five studies addressed the accuracy of\nstudying the diagnostic accuracy of clinical character-                      trigeminal reﬂex testing (Table 3); one study used a\nistics for distinguishing STN from CTN (Table 2). Po-                        prospective design and was graded Class I;[16] the\ntential clinical characteristics studies included: the                       remaining studies, either using a case control design\npresence of sensory deﬁcits, age of onset, ﬁrst division                     with a narrow spectrum of patients or retrospective\nof trigeminal nerve aﬀected, bilateral trigeminal                            data collection, were graded Class II or III.[17,37,38,63]\ninvolvement, and unresponsiveness to treatment.                              The diagnostic accuracy of trigeminal reﬂexes for\n   One study was graded Class III because of a case                          identifying STN patients in most studies was relatively\ncontrol design with a narrow spectrum of patients (De                        high (sensitivity 59 to 100%, speciﬁcity 93 to 100%).\n\n\n                                                                                                                           Ó 2008 The Author(s)\n                                                                    Journal compilation Ó 2008 EFNS European Journal of Neurology 15, 1013–1028\n\fÓ 2008 The Author(s)\n                                                                              Table 6 Medical treatment. Placebo controlled trials\n\n                                                                                                                                                                                                                                                        Duration of\n                                                                                                                                                                       Allocation                                      Improved      Improved           treatment arm &\n                                                                              Author/year         Class No patients                  Intervention    Design            conceal      No. drop outs   Outcomes           on active     on placebo         long-term Follow up\n\n                                                                              Campbell et al.     I      70 (77 patients             CBZ             R, D-B, double    Not stated   Not stated,    Severity of pain,   58%           26%                4 weeks\n                                                                               1966 [14]                  recruited); age             300–800 mg/d    C-O                            possibly none No paroxysms,       68%           26%                No F/U\n                                                                                                          range 20–84                                                                               Trigger inactive   68%           40%\n                                                                              Killian & Fromm     II     24 (30 patients             CBZ            R, D-B, initially  Not stated   3 on active,   Global pain         24/24         0/24 (‘‘response   C-O, 5 days\n                                                                               1968 [36]                  recruited); age             400–1000 mg/d C-O, followed                    placebo not    response            (complete     in all minimal    Extension, 2 weeks to\n                                                                                                          range 36–83                                by closed label                 stated                             or v.good)    or absent’’)       36 months\n                                                                                                                                                     extension\n                                                                              Nicol 1969 [58]     II     44 (of 54 entered)          CBZ            R, D-B, modiﬁed Not stated     10 insufﬁcient   Global pain        15/20 (good 6/7 (good or         C-O, 2 weeks\n                                                                                                                                      100–2400 mg/d C-O, followed                   follow up        response           or excellent) excellent)        F/U up to\n                                                                                                                                                     by closed label                                                                                     46 months\n                                                                                                                                                     extension\n                                                                              Rockcliff & Davis, II      9; age range 37–81          CBZ 600 mg/d R, D-B, C-O,         Independent No drop outs     Patient            8/9           0/9                3 days\n                                                                               1966 [68]                                                             sequential design pharmacist                    preference                                         F/U 7–10 months,\n\n\n\n\nJournal compilation Ó 2008 EFNS European Journal of Neurology 15, 1013–1028\n                                                                                                                                                                                                                                                         median 9 months\n                                                                              Fromm et al. 1984 II       10; age range 59–78         Baclofen        Randomization     Not stated   No drop outs    No. paroxysms      7/10          1/10               1 week\n                                                                               [26]                                                   40–80 mg/d      unclear, D-B,                                                     reduction     reduction         No F/U\n                                                                                                                                                      C-O\n                                                                              Zakrzewska et al.   II     14; age range 44–75     Lamotrigine         R, D-B, C-O,      Not stated   1 on placebo    Composite index, 7/13            1/14               2 weeks\n                                                                               1997 [81]                                          400 mg/d            add on                                         global response                                    No F/U\n                                                                              Fromm 1993 [25]     III    11, age range 41–83;    Tizanidine          Randomization     Not stated   1 on placebo    Frequency of     8/10            4/10               1 week\n                                                                                                          most pts had undergone 12 mg/d              unclear, D-B,                                  paroxysms        reduction       reduction         F/U 6 patients\n                                                                                                          surgery or were on                          C-O                                                                                                (effect lost\n                                                                                                          concurrent medications                                                                                                                         1–3 months)\n                                                                              Kondziolka et al.   I      47; age range 26–82     Proparacaine   R , D-B, C-O           Not stated   No drop outs    Pain score,        6/25          5/25               30 days\n                                                                               1994 [39]                                          0.5% eyedrops                                                      frequency                                          No F/U\n\n                                                                              R, randomized; D-B, double-blind; C-O, cross-over; PG, parallel group, CBZ, carbamazepine; NK, not known\n                                                                                                                                                                                                                                                                                Trigeminal neuralgia management\n                                                                                                                                                                                                                                                                                1017\n\f1018                                                                         G. Crucca et al.\n\n\n\n                                                                                                                                                                                                                                                                                                                                              Pooled sensitivity 94% (95% CI, 91 to 97); pooled\n\n\n\n\n                                                                                                    Duration of F/U not\n                                                                       long-term Follow up\n                                                                                                                                                                                                                                                                                                                                              speciﬁcity 87% (95% CI, 77 to 93). Four studies ad-\n\n                                                                       treatment arm &\n                                                                       Duration of                                                                                                                                                                                                                                                            dressed the accuracy of evoked potential (Table 4), two\n\n\n\n\n                                                                                                    6–32 weeks\n\n\n\n\n                                                                                                                                                        6–8 weeks\n                                                                                                                                                                                                                                                                                                                                              attaining a grade of Class II and two Class\n\n\n                                                                                                    No F/U\n                                                                                                    2 weeks\n\n                                                                                                    8 weeks\n\n                                                                                                     stated\n                                                                                                                                                                                                                                                                                                                                              III.[17,18,41,58] The diagnostic accuracy of evoked\n                                                                                                                                                                                                                                                                                                                                              potentials for identifying STN patients was moderate\n                                                                                                                                                                                                                                                                                                                                              (sensitivity 60 to 100%, speciﬁcity 49 to 76%). Pooled\n                                                                       comparator\n\n\n\n\n                                                                                                                                                                                                                                                                                                                                              sensitivity 84% (95% CI, 73 to 92); pooled speciﬁcity\n                                                                       Improved\n\n\n\n\n                                                                                                                                                                                                                                                                                                                                              64% (95% CI, 56 to 71).\n\n\n\n\n                                                                                                                                                                               R, randomized; D-B, double-blind; C-O, cross-over; PG, parallel group, CBZ, carbamazepine; OXC, oxcarbazepine; PMZ, pimozide; TOC, tocainide; NK, not known;\n                                                                                                    10/12\n\n                                                                                                                     27/48\n\n\n                                                                                                                                     19/20\n\n\n\n\n                                                                                                                                                        54/61\n                                                                       on\n\n\n\n\n                                                                                                                                                                                                                                                                                                                                              Conclusions. For patients with TN, involvement of the\n                                                                                                                                                                                                                                                                                                                                              ﬁrst division of the trigeminal nerve and unrespon-\n                                                                       Improved\n                                                                       on study\n\n\n\n\n                                                                                                                                                                                                                                                                                                                                              siveness to treatment are probably not associated with\n                                                                                                                     48/48\n\n\n                                                                                                                                     24/24\n\n\n\n\n                                                                                                                                                        63/69\n                                                                       drug\n\n                                                                                                    9/12\n\n\n\n\n                                                                                                                                                                                                                                                                                                                                              an increased risk of STN. (One Class I, two Class II).\n                                                                                                                                                         attacks, (evoked                                                                                                                                                                     Younger age (one Class I, three Class II studies) and\n                                                                                                                                                                                                                                                                                                                                              abnormal trigeminal nerve evoked potentials (two class\n                                                                                                                                      in TN attacks\n                                                                                                                                     50% reduction\n                                                                                                                      ‘‘TN score’’\n\n\n\n\n                                                                                                                                                                                                                                                                                                                                              II and two Class III studies) are probably associated\n                                                                                                                                                         pain global\n                                                                                                    Global pain\n\n\n\n\n                                                                                                                                                        No. weekly\n                                                                                                                     Composite\n                                                                                     Outcomes\n\n\n\n\n                                                                                                                                                         efﬁcacy)\n                                                                                                                                                                                                                                                                                                                                              with an increased risk of STN. However, there is too\n                                                                                                                                                                                                                                                                                                                                              much overlap in patients with CTN and STN for these\n                                                                                                                                                                                                                                                                                                                                              predictors to be considered clinically useful. The pres-\n                                                                                                                                                                                                                                                                                                                                              ence of trigeminal sensory deﬁcits or bilateral involve-\n                                                                              drop outs\n\n\n\n\n                                                                                                    CBZ not\n\n\n\n\n                                                                                                                                                                                                                                                                                                                                              ment of the trigeminal nerves probably increases the\n                                                                                                    PMZ 0\n\n\n                                                                                                    OXC 0\n                                                                                                     stated\n                                                                                                    TOC 0\n                                                                                                    CBZ 0\n\n\n\n\n                                                                                                    CBZ 2\n\n\n\n\n                                                                                                                                                                                                                                                                                                                                              risk of STN. However, the absence of these features\n                                                                              No.\n\n\n\n\n                                                                                                                                                                                        ",
  "wordCount": 10347,
  "indexed": "2025-09-25T22:55:53.888Z",
  "method": "direct"
}
